Cargando…

BRCA Variants Do Not Increase the Risk of Adverse Reactions in Patients With Ovarian Cancer: A Single-Center Real-World Study

OBJECTIVE: To study the correlation between BRCA mutation status and the risk of adverse reactions in patients with ovarian cancer. METHOD: A real-world study was conducted at the largest gynecological oncology center in western China, the West China Second University Hospital of Sichuan University....

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Kemin, Zeng, Jing, Zhang, Mengpei, Yin, Rutie, Li, Zhengyu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9279692/ https://www.ncbi.nlm.nih.gov/pubmed/35847868 http://dx.doi.org/10.3389/fonc.2022.807748

Ejemplares similares

Monotherapy for low-risk gestational trophoblastic neoplasia with score 5-6
por: Kemin, Li, et al.
Publicado: (2022)

Frailty and long-term survival of patients with ovarian cancer: A systematic review and meta-analysis
por: Li, Kemin, et al.
Publicado: (2022)

Different dose series of human papillomavirus vaccine in young females: a pair-wise meta-analysis and network meta-analysis from randomized controlled trials
por: Kemin, Li, et al.
Publicado: (2023)

A new pathogenic mutation of the BRCA1 gene in a patient with ovarian cancer: A case report
por: Yizhen, Niu, et al.
Publicado: (2018)

Landscape of germline BRCA1/BRCA2 variants in breast and ovarian cancer in Peru
por: Ferreyra, Yomali, et al.
Publicado: (2023)

Tumor Testing for Somatic and Germline BRCA1/BRCA2 Variants in Ovarian Cancer Patients in the Context of Strong Founder Effects
por: Peixoto, Ana, et al.
Publicado: (2020)

Prevalence and Spectrum of Germline BRCA1 and BRCA2 Variants of Uncertain Significance in Breast/Ovarian Cancer: Mysterious Signals From the Genome
por: Fanale, Daniele, et al.
Publicado: (2021)

Ovarian Real-World International Consortium (ORWIC): A multicentre, real-world analysis of epithelial ovarian cancer treatment and outcomes
por: Cheeseman, Sue, et al.
Publicado: (2023)

GEMO, a National Resource to Study Genetic Modifiers of Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Pathogenic Variant Carriers
por: Lesueur, Fabienne, et al.
Publicado: (2018)

Erratum: Prevalence and Spectrum of Germline BRCA1 and BRCA2 Variants of Uncertain Significance in Breast/Ovarian Cancer: Mysterious Signals From the Genome
Publicado: (2022)

BRCA and Early Events in the Development of Serous Ovarian Cancer
por: George, Sophia H. L., et al.
Publicado: (2014)

Assessment of the Prognostic Value of Two Common Variants of BRCA1 and BRCA2 Genes in Ovarian Cancer Patients Treated with Cisplatin and Paclitaxel: A Gynecologic Oncology Group Study
por: Tian, Chunqiao Q., et al.
Publicado: (2013)

Beyond Breast and Ovarian Cancers: PARP Inhibitors for BRCA Mutation-Associated and BRCA-Like Solid Tumors
por: O’Sullivan, Ciara C., et al.
Publicado: (2014)

Real-World Efficacy of Bevacizumab in Patients With Recurrent Epithelial Ovarian Cancer
por: Hung, Jo-Ni, et al.
Publicado: (2022)

Characterization of global research trends and prospects on platinum-resistant ovarian cancer: a bibliometric analysis
por: Duan, Yuanqiong, et al.
Publicado: (2023)

Melphalan as a Promising Treatment for BRCA-Related Ovarian Carcinoma
por: Conteduca, Vincenza, et al.
Publicado: (2021)

Real World Experience of Daratumumab: Evaluating Lymphopenia and Adverse Events in Multiple Myeloma Patients
por: Cottini, Francesca, et al.
Publicado: (2021)

Interdisciplinary risk counseling for hereditary breast and ovarian cancer: real-world data from a specialized center
por: Zang, Benedikt, et al.
Publicado: (2022)

What predicts the clinical benefits of PARP inhibitors in platinum-sensitive recurrent ovarian cancer: A real-world single-center retrospective cohort study from China
por: Zhang, Depu, et al.
Publicado: (2022)

Characterization of Synonymous BRCA1:c.132C>T as a Pathogenic Variant
por: Li, Jun, et al.
Publicado: (2022)

Repeat Cytology and Human Papillomavirus Screening Strategies in Detecting Preinvasive Cervical Lesions
por: Li, Kemin, et al.
Publicado: (2015)

Quantitative Analysis of BRCA1 and BRCA2 Germline Splicing Variants Using a Novel RNA-Massively Parallel Sequencing Assay
por: Farber-Katz, Suzette, et al.
Publicado: (2018)

Cost-Effectiveness of BRCA 1/2 Genetic Test and Preventive Strategies: Using Real-World Data From an Upper-Middle Income Country
por: Lourenção, Marina, et al.
Publicado: (2022)

Genomic Profile and BRCA-1 Promoter Methylation Status in BRCA Mutated Ovarian Cancer: New Insights in Predictive Biomarkers of Olaparib Response
por: Franzese, Elisena, et al.
Publicado: (2019)

Germline and Somatic BRCA1/2 Mutations in 172 Chinese Women With Epithelial Ovarian Cancer
por: You, Yan, et al.
Publicado: (2020)

Hypoxia-Activated Alkylating Agents in BRCA1-Mutant Ovarian Serous Carcinoma
por: Conroy, Michael, et al.
Publicado: (2017)

Sustained delivery of PARP inhibitor Talazoparib for the treatment of BRCA-deficient ovarian cancer
por: Yang, Shicheng, et al.
Publicado: (2023)

Real-World Impact of Survival by Period of Diagnosis in Epithelial Ovarian Cancer Between 1990 and 2014
por: Wu, San-Gang, et al.
Publicado: (2019)

Diagnosis and treatment of uterine sarcoma: A multicenter, real-world study in western China
por: Li, Kemin, et al.
Publicado: (2021)

Efficacy and safety of treatment regimens for patients with metastatic, locally advanced, or recurrent breast cancer carrying BRCA1/BRCA2 pathogenic variants: A network meta-analysis
por: Zhu, Yingxuan, et al.
Publicado: (2023)

Identification of BRCA1:c.5470_5477del as a Founder Mutation in Chinese Ovarian Cancer Patients
por: Li, Jun, et al.
Publicado: (2021)

Prediction Models for Complete Resection in Secondary Cytoreductive Surgery of Patients With Recurrent Ovarian Cancer
por: Jiang, Caixia, et al.
Publicado: (2021)

Editorial: Real-world data and real-world evidence in hematologic malignancies
por: Malagola, Michele, et al.
Publicado: (2023)

A Multi-Center, Real-World Study of Chidamide for Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas in China
por: Liu, Weiping, et al.
Publicado: (2021)

Assessing real-world safety concerns of Sacituzumab govitecan: a disproportionality analysis using spontaneous reports in the FDA adverse event reporting system
por: Gui, Xiujuan, et al.
Publicado: (2023)

Ostomy Does Not Lead to Worse Outcomes After Bowel Resection With Ovarian Cancer: A Systematic Review
por: He, Xinlin, et al.
Publicado: (2022)

Corrigendum: Identification of BRCA1:c.5470_5477del as a Founder Mutation in Chinese Ovarian Cancer Patients
por: Li, Jun, et al.
Publicado: (2022)

Comparison of Laparoscopic and Open Surgery for Women With Early-Stage Epithelial Ovarian Cancer
por: Ran, Xuting, et al.
Publicado: (2022)

Apatinib Plus Camrelizumab With/Without Chemoembolization for Hepatocellular Carcinoma: A Real-World Experience of a Single Center
por: Ju, Shuguang, et al.
Publicado: (2022)

Update on Poly ADP-Ribose Polymerase Inhibitors in Ovarian Cancer With Non-BRCA Mutations
por: Xu, Qin, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_763o0uh7ekl8m9dvcrk6b720t2